HLA Genotyping Supports a Nonautoimmune Etiology in Patients Diagnosed With Diabetes Under the Age of 6 Months
暂无分享,去创建一个
P. Bingley | A. Hattersley | S. Ellard | S. Flanagan | E. L. Edghill | R. Dix | K. Gillespie | R. J. Dix | Rachel J. Dix
[1] F. Ashcroft,et al. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. , 2005, Diabetes.
[2] Å. Lernmark,et al. Diabetes-associated HLA genotypes affect birthweight in the general population , 2005, Diabetologia.
[3] S. Ellard,et al. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation , 2005, Diabetologia.
[4] A. Hattersley,et al. High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. , 2005, Diabetes care.
[5] A. Hattersley,et al. KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes , 2005, Human mutation.
[6] B. Glaser,et al. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. , 2004, The Journal of clinical endocrinology and metabolism.
[7] A. Hattersley,et al. Activating mutations in the KCNJ11 gene encoding the ATP-sensitive K+ channel subunit Kir6.2 are rare in clinically defined type 1 diabetes diagnosed before 2 years. , 2004, Diabetes.
[8] A. Hattersley,et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. , 2004, Diabetes.
[9] A. Hattersley,et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. , 2004, Diabetes.
[10] A. Hattersley,et al. Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. , 2004, The Journal of clinical endocrinology and metabolism.
[11] F. Ashcroft,et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. , 2004, The New England journal of medicine.
[12] A. Hattersley,et al. Genetic cause of hyperglycaemia and response to treatment in diabetes , 2003, The Lancet.
[13] A. Hattersley,et al. Genetic Aetiology of Hyperglycaemia Alters Response to Treatment in Diabetes , 2003 .
[14] M. Martinetti,et al. Permanent diabetes mellitus in the first year of life , 2002, Diabetologia.
[15] N. Keiding,et al. Correlations between the incidence of childhood-onset Type I diabetes in Europe and HLA genotypes , 2001, Diabetologia.
[16] A. Molven,et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. , 2001, The New England journal of medicine.
[17] J. Shield. Neonatal Diabetes: New Insights into Aetiology and Implications , 2000, Hormone Research in Paediatrics.
[18] A. Hattersley,et al. The fetal insulin hypothesis: an alternative explanation of the association of low bir thweight with diabetes and vascular disease , 1999, The Lancet.
[19] P. Bingley,et al. Prediction of IDDM in the General Population: Strategies Based on Combinations of Autoantibody Markers , 1997, Diabetes.
[20] J. L. Botha,et al. Diabetes diagnosed before the age of 2 years: mortality in a British cohort 8-17 years after onset. , 1992, International journal of epidemiology.
[21] J. Todd,et al. Regression mapping of association between the human leukocyte antigen region and Graves disease. , 2005, American journal of human genetics.
[22] G. Eisenbarth,et al. 17. Immunologic endocrine disorders. , 2003, The Journal of allergy and clinical immunology.